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Midterm results of a Novel Interatrial Shunt Therapy for Heart Failure and Preserved Ejection Fraction Background: Approximately 50% of patients presenting with clinical features of heart failure have a preserved ejection fraction ("HFPEF"). The fundamental pathophysiologic basis for the HFPEF phenotype is impaired diastolic reserve, with elevated resting, or rapid increase in LVEDP, LAP and pulmonary artery pressures during low level physical activity. We report the midterm results of a novel device intended to lower left atrial pressure by creating a small permanent atrial septal shunt. Objective: Evaluation of safety and potential benefits of the intra atrial shunt device (IASDTM) System in patients with symptomatic heart failure with preserved or mildly reduced ejection fraction, despite appropriate medical management Methods: Eleven patients were enrolled under an approved protocol in a prospective multicenter feasibility study. Key inclusion criteria were: EF > 45%; PCWP at rest ! 15 or exercise ! 25mm Hg; ! 1 hospitalization for heart failure within prior 12 months, or persistent NYHA Class III/IV for at least 3 months. Results: Mean age, and EF, were 75 Y, and 57 %, respectively. Most patients had multiple comorbidities. The IASD Device was successfully implanted in each patient. Two SAE occurred within 30 days, and both were resolved. At 30-90 days, PCWP was reduced (4 mmHg, P< 0.001) with no change in CVP, and at 6 months clinical symptoms had improved (See Table) . One year follow-up data will be presented.
Conclusions:
This initial data demonstrates that the shunt device can be safely implanted and that midterm clinical improvement can be obtained in patients with heart failure and preserved or mildly reduced ejection fraction.
TCT-78
Predictors Background: Left ventricular assist devices (LVADs) have been shown to increase survival and quality of life in patients with end-stage congestive heart failure. However, severe aortic insufficiency (AI) can develop in up to 50% of patients with LVADs at 12 months resulting in significant morbidity and mortality. Trans-catheter treatment of LVAD associated AI has emerged as a potential alternative to surgical treatment, but long term clinical benefits are yet to be determined. Methods: We conducted a retrospective analysis of all patients undergoing transcatheter aortic valve closure using an Amplatzer Multi-Fenestrated Septal Occluder "Cribiform" device (AGA Medical, Plymouth, Minnesota) at our institution between September 2011 and September 2013 to assess potential clinical and procedural factors associated with survival. Unpaired student's t-tests were used to compare baseline patient demographics and procedural characteristics, as well as patient outcomes immediately post procedure and at 6 months. A p-value of < 0.05 was considered statistically significant. Results: A total of 8 patients (75% male, median age 59 years) were included in this analysis. Technical success of the procedure including total cessation of AI without evidence of coronary compromise was accomplished in 100% of patients with a 6 month survival rate of 38% (3/8). Predictors of survival include the absence of significant co-morbidities such as chronic renal insufficiency, smaller occlusion device placement, and the absence of right heart failure ( Table 1) .
Conclusions: Trans-catheter aortic valve closure successfully treats late severe AI in LVAD patients, however, the presence or development of right heart failure portends a worse prognosis. Further studies are needed to investigate the potential right ventricular failure in patients undergoing trans-catheter aortic valve closure. www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5 :00 PM-7:00 PM JACC Vol 64/11/Suppl B j September 13-17, 2014 j TCT Abstracts/Heart Failure Therapies B23
